Screening for novel HDAC-inhibitors targeting epigenetically dysregulated cell differentiation in triple-negative breast cancer

被引：0
|
作者：
Kulik, A. [1 ]
Esser, K. [1 ]
Niederacher, D. [1 ]
Neubauer, H. [1 ]
Kurz, T. [2 ]
Fehm, T. [1 ]
机构：
[1] Heinrich Heine Univ Dusseldorf, Dept Obstet & Gynecol, Life Sci Ctr, Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Inst Pharmaceut & Med Chem, Duseldorf, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2020年 / 80卷 / 06期
关键词：
D O I：
10.1055/s-0040-1714584
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
74
引用
收藏
页码：E44 / E44
页数：1
相关论文
共 50 条
  • [41] BCL11A—targeting triple-negative breast cancer?
    Alessia Errico
    Nature Reviews Clinical Oncology, 2015, 12 (3) : 127 - 127
  • [42] Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform!
    Guadagni, Anna
    Barone, Simona
    Alfano, Antonella Ilenia
    Pelliccia, Sveva
    Bello, Ivana
    Panza, Elisabetta
    Summa, Vincenzo
    Brindisi, Margherita
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 279
  • [43] Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
    de Paula, Bruno
    Kieran, Rosalind
    Koh, Samantha Shui Yuan
    Crocamo, Susanne
    Abdelhay, Eliana
    Mun, Daniel
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (05) : 583 - 598
  • [44] Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer
    Jiang, Xin-Chen
    Tu, Fang-Hai
    Wei, Li-Yuan
    Wang, Bo-Zheng
    Yuan, Hao
    Yuan, Jing-Mei
    Rao, Yong
    Huang, Shi-Liang
    Li, Qing-Jiang
    Ou, Tian-Miao
    Wang, Hong-Gen
    Tan, Jia-Heng
    Chen, Shuo-Bin
    Huang, Zhi-Shu
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, : 12346 - 12366
  • [45] Targeting tankyrases as a therapeutic strategy for triple-negative breast cancer
    Mathew, Maya
    Campo, Loredana
    Kim, Jung-Lye
    Ha, Geun-Hyoung
    Breuer, Eun-Kyoung
    CANCER RESEARCH, 2017, 77
  • [46] Targeting a cell state common to triple-negative breast cancers
    Muellner, Markus K.
    Mair, Barbara
    Ibrahim, Yasir
    Kerzendorfer, Claudia
    Lechtermann, Hannelore
    Trefzer, Claudia
    Klepsch, Freya
    Mueller, Andre C.
    Leitner, Ernestine
    Macho-Maschler, Sabine
    Superti-Furga, Giulio
    Bennett, Keiryn L.
    Baselga, Jose
    Rix, Uwe
    Kubicek, Stefan
    Colinge, Jacques
    Serra, Violeta
    Nijman, Sebastian M. B.
    MOLECULAR SYSTEMS BIOLOGY, 2015, 11 (02)
  • [47] Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
    van der Noord, Vera E.
    van de Water, Bob
    Le Devedec, Sylvia E.
    CANCERS, 2022, 14 (18)
  • [48] Emerging Novel Therapeutics in Triple-Negative Breast Cancer
    Lyons, Tomas G.
    Traina, Tiffany A.
    BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, 2019, 1152 : 377 - 399
  • [49] Design, Screening and Development of Asymmetric siRNAs Targeting the MYC Oncogene in Triple-Negative Breast Cancer
    Mekonnen, Negesse
    Seo, Myeung-Ryun
    Yang, Hobin
    Chelakkot, Chaithanya
    Choi, Jun Young
    Hong, Sungyoul
    Song, Kyoung
    Shin, Young Kee
    BIOMOLECULES & THERAPEUTICS, 2025, 33 (01) : 155 - 169
  • [50] Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
    Boscolo Bielo, Luca
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 789 - 801
12345